Merck, Eisai to Discontinue Late-Stage Study for Skin Cancer

Merck and Eisai said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma.

Related Keywords

Bengaluru ,Karnataka ,India ,Raghav Mahobe ,Eisai Lenvima ,Jan Harvey ,Jason Neely ,Eisai Co Ltd ,Merck Co Inc ,Reuters ,Skin Cancer ,Alignant Skin Neoplasm ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Vegf Inhibitor ,Vascular Endothelial Growth Factor Inhibitor ,Monoclonal Antibody ,Etuximab ,Ituximab ,Biologic Therapy ,Iologics ,Melanoma ,Malignant Melanoma ,